Big Pharma
1 July 2025 French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.
1 July 2025
30 June 2025
Latest Features
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
The act’s one-sided provisions and its disproportionate remedies cannot pass constitutional muster, argues John Cox of Barnes & Thornburg.
Asia
Recent updates to China’s patent law provide guidelines on PTA calculations, definitions of delays and challenging decisions, say Audrey Cheung, Yolanda Wang and Jennifer Che of Eagle IP.
Americas
Can the FTC push through a law that has perturbed America’s life sciences industry? Unlikely, says the lawyer appointed by the world’s largest HR group opposing the move.
Europe
As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.
More News
24 June 2025 Appeals board overturns previous decision and revokes patent on treatment worth $2bn in 2024 | Teva and Generics UK successful in arguing lack of inventive step.
19 June 2025 Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to Kirkland’s prior work for Regeneron | Kirkland denies conflict, citing screening measures.
17 June 2025 Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.
5 June 2025 Biotech company convinces judges over claim construction interpretation | Alnylam “acted as lexicographer” regarding a claim term | Win comes as Moderna suffers economic challenges.
5 June 2025 Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.
29 May 2025 Novo Nordisk faces resistance from Connecticut clinic in Ozempic and Wegovy dispute | LIVation admits to referencing Novo Nordisk products in past marketing but it has since been removed | Clinic claims its compounded semaglutide use was lawful and clear to patients.
29 May 2025 Shilpa Medicare failed to prove invalidity of patent covering Lenvima | Eisai says ruling keeps India-based generic maker’s product off the market until 2036.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox